- Acne
- Actinic Keratosis
- Aesthetics
- Alopecia
- Atopic Dermatitis
- Buy-and-Bill
- COVID-19
- Case-Based Roundtable
- Chronic Hand Eczema
- Drug Watch
- Eczema
- General Dermatology
- Hidradenitis Suppurativa
- Melasma
- NP and PA
- Pediatric Dermatology
- Pigmentary Disorders
- Practice Management
- Precision Medicine and Biologics
- Prurigo Nodularis
- Psoriasis
- Psoriatic Arthritis
- Rare Disease
- Rosacea
- Skin Cancer
- Vitiligo
- Wound Care
Maximizing Impact and Utility of Prognostic Gene Testing in Melanoma and Squamous Cell Carcinoma : Episode 5
Opinion
Video
De-Escalating Treatment Plans With Gene Expression Profiling in an 80-Year-Old Man With SCC
Author(s):
An expert discusses their impressions of the case, classifying the patient’s risk based on the clinical presentation of the lesion, and outlines treatment recommendations without knowing the 40-gene expression profile (GEP) information, including whether adjuvant therapy (ART) would be recommended. The expert also shares how to discuss 40-GEP testing with patients and reassure them that accurate risk levels are crucial for receiving optimal treatment.
Video Player is loading.
Video content above is prompted by the following:
- What are your impressions of this case? Based on the clinical presentation of the lesion, how would you classify the patient’s risk?
- Without knowing the 40-GEP information, what would your treatment recommendation be? Would you recommend ART for this patient?
- How do you discuss 40-GEP testing with your patients? How can you best reassure patients that an accurate risk level is critical to receiving optimal treatment?
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Related Videos
Safety Considerations for IL-17 Inhibitors
Selecting and Dosing IL-17 Inhibitors in Psoriasis
Key Takeaways on GEP Testing in Melanoma and SCC
Switching from Biologics to JAK Inhibitors in Nonresponders and Dose Escalation
Balancing Education and Reassurance: Guiding Parents Through the Safety Profile of New Therapies
Essential Monitoring Considerations for Prescribing Topical JAK Inhibitors in Younger Children
Evaluating the Safety of Topical JAK Inhibitors in the Pediatric Population: Insights into Systemic Risks and Adverse Effects
Overcoming Therapeutic Inertia in a 25-Year-Old Man with Moderate to Severe Atopic Dermatitis
Safety Considerations in Pediatric Atopic Dermatitis Treatments
Quality of Life Impact: Supporting Patients With GPP
Related Content
